The pharma services sector continues to show strong momentum through 2025 as demand for outsourced solutions accelerates across drug development, manufacturing, and commercialization. In our latest Pharma Services Market Update, we break down key trends shaping the space and where investors are finding the most attractive opportunities.

Key Highlights:

• Sustained growth across CDMO and CRO segments: Pharma and biotech companies continue to lean on outsourcing partners to enhance efficiency, reduce risk, and accelerate speed to market—driving solid performance across the sector.

• M&A activity remains healthy: Consolidation continues as both strategic and financial buyers pursue scale, technical expertise, and integrated service offerings across the value chain.

• Innovation and specialization as differentiators: Differentiated capabilities in biologics, cell and gene therapy, and complex formulations are attracting strong valuation premiums and investor interest.

• Looking ahead: Long-term fundamentals remain positive, underpinned by strong pipelines, regulatory clarity, and continued demand for innovation support from pharma partners.

Read the full report here: Founders Advisors Pharma Services Market Update – Q3 2025

If you’d like to discuss trends or strategic opportunities in the pharma services space, reach out to Michael White, Managing Director in our Healthcare Practice at Founders Advisors.